JOURNAL OF NEUROSURGERY, vol.117, no.4, pp.697-704, 2012 (Journal Indexed in SCI)
Object. Angiogenesis and the platelet-derived growth factor (PDGF) pathway are active in the pathogenesis of vestibular schwannomas (VSs). The purpose of this study was to test whether imatinib mesylate (Gleevec), a PDGF receptor (PDGFR) blocker, reduces angiogenic capacity in sporadic VS and in VS associated with neurofibromatosis Type 2 (NF2) using a conical angiogenesis assay.